We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Eco Animal Health Group Plc | LSE:EAH | London | Ordinary Share | GB0032036807 | ORD 5P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -1.00 | -1.33% | 74.00 | 71,111 | 15:27:19 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 72.00 | 76.00 | 75.00 | 74.00 | 75.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Chem,fertlizer Minrl Mng,nec | 89.42M | 1.05M | 0.0155 | 47.74 | 50.81M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 15:45:58 | O | 43,880 | 72.50 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 01/10/2024 | 12:28 | ALNC |  ECO Animal Health shares fall as to underperform market expectations |
| 01/10/2024 | 07:00 | UK RNS | Eco Animal Health Group PLC Trading Update |
| 27/9/2024 | 14:21 | UK RNS | Eco Animal Health Group PLC Result of AGM |
| 30/8/2024 | 15:07 | UK RNS | Eco Animal Health Group PLC Director/PDMR Shareholding |
| 29/8/2024 | 07:00 | UK RNS | Eco Animal Health Group PLC Deferred Share Option Award to Executive.. |
| 23/8/2024 | 13:18 | UK RNS | Eco Animal Health Group PLC Holding(s) in Company |
| 16/8/2024 | 07:00 | UK RNS | Eco Animal Health Group PLC Posting of the Annual Report and Notice of AGM |
| 12/8/2024 | 13:30 | UK RNS | Eco Animal Health Group PLC Block Listing Interim Review |
| 15/7/2024 | 12:49 | ALNC | ECO Animal targets sustained growth with expanded product range |
| 15/7/2024 | 07:00 | UK RNS | Eco Animal Health Group PLC Final Results |
Eco Animal Health (EAH) Share Charts1 Year Eco Animal Health Chart |
|
1 Month Eco Animal Health Chart |
Intraday Eco Animal Health Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 01/10/2024 | 10:09 | Eco Animal Health Group: Early dewormer gets OK | 1,564 |
| 05/4/2024 | 10:45 | Eco Animal Health | - |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-10-03 16:15:00 | 72.50 | 43,880 | 31,813.00 | O |
| 2024-10-03 14:45:59 | 72.65 | 783 | 568.85 | O |
| 2024-10-03 14:27:21 | 72.60 | 1,960 | 1,422.96 | O |
| 2024-10-03 14:26:34 | 74.30 | 5,000 | 3,715.00 | O |
| 2024-10-03 14:25:23 | 74.30 | 5,000 | 3,715.00 | O |
| Top Posts |
|---|
Posted at 03/10/2024 09:20 by Eco Animal Health Daily Update Eco Animal Health Group Plc is listed in the Chem,fertlizer Minrl Mng,nec sector of the London Stock Exchange with ticker EAH. The last closing price for Eco Animal Health was 75p.Eco Animal Health currently has 67,744,889 shares in issue. The market capitalisation of Eco Animal Health is £50,131,218. Eco Animal Health has a price to earnings ratio (PE ratio) of 47.74. This morning EAH shares opened at 75p |
Posted at 01/10/2024 08:52 by its the oxman Yep strong value in its r and d and approved products , arguably way above current price. Will be realised one day if you can stomach the current disappointment. Tough one. |
Posted at 01/10/2024 08:12 by boonkoh Broker forecast cuts now in. Equity Dev and Singer -10% and -13% ebitda for FY25. Moderate mild cuts.Singer maintains price target of 258p (!!) saying value in EAH is the upcoming new product launches in 2025-2026. Let's see if the market agrees...(I hold in the Boon Fund) |
Posted at 01/10/2024 07:38 by edmonda Trading Update: headwinds in China - new research note: In a Trading Update for the six months to 30 September 2024, ECO Animal Health reports reduced demand in China and SE Asia markets for its proprietary Aivlosin® porcine treatment, reflecting lower incidence of disease and some customer churn. The Group expects the customary H2 earnings weighting (H2 FY24: 57.5%), whilst Aivlosin® continues to gain market share in India and Brazil. However, the combination of demand, foreign exchange and other factors across the full range of EAH’s global market presence leads the company at this stage to assess that revenue for the full year should be below market estimates: a consensus indicated of £92.6m and (adj.) EBITDA of £8.2m. Consequently the Group expects FY25 (adj.) EBITDA to be close to FY23 levels (£7.2m). At this stage we have adjusted our FY25 outlook accordingly. Our FY25 revenue estimate is reduced by 7%, and (adj.) EBITDA by 10%. We remain prudent but will review further as H2 develops. |
Posted at 01/10/2024 07:23 by waldron Eco Animal Health Group PLC Trading Update01/10/2024 7:00am RNS Regulatory News RNS Number : 3399G Eco Animal Health Group PLC 01 October 2024 1 October 2024 ECO Animal Health Group plc ("ECO" or the "Company") Trading Update ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, today announces an update on its trading for the six months ending 30 September 2024. Aivlosin® continues to gain market share in key territories, particularly Brazil and India, with revenues in these regions exceeding the Board's expectations. In addition, and as expected, we are continuing to gain market share in the US. We are however, encountering challenges in China, due to low disease incidence in the summer months, and in Southeast Asia, where sales have slowed reflecting some customer churn. The ECO Group is second half weighted and this pattern will continue in FY 2025. Nevertheless, the recent challenges we've faced in China and Southeast Asia lead us to believe that revenue for the full year will be materially below market expectations.1 Due to the complex mix of geographies in which the ECO Group operates, foreign exchange headwinds, and the differing gross margins across each region, forecasting an adjusted EBITDA figure for the full year at this stage is challenging. The Board expects that adjusted EBITDA for FY25 will be in the region of that observed in FY23 and notes it is likely that more accurate guidance will be provided when interim results to 30 September 2024 are announced in late November.2 The ECO Group has grounds for optimism for an improved performance in the second half with pork prices improving in China, strong order books and continuing strength in North America, Brazil and India. In addition, we have recently been notified that the ECO Group has received regulatory approval for the marketing of Aivlosin® in Paraguay. This market produced 1.4m pigs in 2023, nearly 80% of which were in industrial farms. The ECO Group is strongly cash generative and has a non-China cash balance in-line with that on hand at 31 March 2024. This ensures that the ECO Group's valuable R&D programme continues to move forward on a self-funded basis at the planned rate. 1. The Board understands market expectations for revenue and EBITDA in FY25 is £92.6m and £8.2m respectively. 2. Reported audited revenue and adj EBITDA for FY23 was £85.3m and £7.2m respectively. -Ends- |
Posted at 30/8/2024 10:14 by cerrito saw this.Those of you who were more on the ball than me and who bought a couple of weeks back in the mid 90's will not regret it. quote Vet pharmaceutical group Eco Animal Health (EAH) could be through its nadir and on the cusp of an attractive period of growth, says Shore Capital. Analyst Sean Conroy retained his ‘buy’ recommendation and a ‘fair value’ target price of 175p on the stock, which softened 0.8% to 106.7p on Tuesday, putting it down 2.1% over the last year. Full-year 2024 results from the group ‘evidenced a robust performance from Aivlosin (used in drinking water for turkeys and chickens), which underpinned the delivery of +11% top-line growth despite the recent, challenging period its customers have faced’. unquote ‘We sense the sentiment nadir could be passing with respect to the current lull in the hog cycle and highlight that Eco Animal Health should benefit if pork producers continue to return to profitability,’ The next 18 months will ‘represent a pivotal period’ as the company looks to secure regulatory approvals and launch new products, and ‘looks set to offer an attractive period of near-term growth’. |
Posted at 16/8/2024 07:15 by grupo guitarlumber ECO Animal Health Group plc("ECO" or the "Company") Posting of the Annual Report and Notice of AGM ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that its Annual Report and Accounts for the year ended 31 March 2024 and Notice of Annual General Meeting ("AGM") together with Form of Proxy have today been sent to shareholders who have elected to receive hard copies by post. The Annual Report and Accounts is available on the Company's website at The Company will hold its AGM at The Grange, 100 High Street, London, N14 6BN on Thursday, 26 September 2024 at 9:00 am. A copy of the Notice of AGM and Form of Proxy will be available on the Company's website at -Ends- |
Posted at 15/7/2024 07:21 by edmonda ECO Animal Health (LON:EAH) - "Strong FY24 results: 11% underlying growth", new note available here: For the year ended 31st March 2024, ECO Animal Health Group reported revenue +5%YoY at £89.4m, which on a currency-adjusted basis was +11%YoY, and (adj.) EBITDA of £8.0m, +11.2%YoY which was ahead of market consensus on an improvement in margin from 8.5% to 9.0%. The impact of currency volatility was evident in gross profitability at 42.1% compared to 45.0% a year earlier; H2 recovered to 43.1%. (Adj.) EBIT was 14%YoY lower at £4.6m, a 5.1% margin compared to 6.3% in FY23. Having rallied 30%YoY, EAH shares are trading 7% off its recent year high. We have derived a Fair Value per share range of 137p-146p based on the initial, medium-term, valuation of the pipeline of products under development. |
Posted at 09/4/2024 11:57 by boonkoh Seems to me that Schroders has cleared an overhang which was weighing down on the share price?Nice rise today on small volumes. |
Posted at 23/3/2024 14:26 by cerrito I found this on Citywirequote Vet pharmaceutical group Eco Animal Health (EAH) delivered a ‘reassuringly positive’ trading update and is offering both growth and value, says Shore Capital. Analyst Sean Conroy retained his ‘buy’ recommendation and a ‘fair value’ target price of 175p on the stock, which climbed 2.9%, or 2.5p, to 88p yesterday after ‘delivering robust growth in the current environment’ owing to its ‘commercial prowess’. Although the group has not been immune from recent weakness in pork prices it has demonstrated ‘a high degree of resilience to the ongoing lull in the hog cycle’. Conroy said the shares are trading on an embedded value to pre-tax earnings ratio of 5.9 times for 2025 and 5.3 times for 2025, which is a ‘sizeable discount to animal health peers on 12 times and 11 times, respectively’. He said the stock should trade closer to peers, inferring 100% upside to the share price. ‘Securing regulatory approvals for its Mycoplasma poultry vaccines in the first half 2025 should provide a catalyst to allow more value to be ascribed to the pipeline,’ he said. ‘However, when discounting the dynamics of the development pipeline from our model, we still value the underlying commercial business at 150p and hence, we see a good buying opportunity from both a growth and value perspective.’ |
Posted at 09/1/2023 09:10 by cerrito Given the ANP news this morning especially with reference to China was expecting a slight fall here but of course the current EAH share price has alot of bad-even if transitory - news baked in. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
